MedTrace Logo

AMG 745 in Subjects With Age-associated Muscle Loss

NCT00975104 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-10-04

No results posted yet for this study

Summary

Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss

Conditions

  • Age-associated Muscle Loss

Interventions

DRUG

AMG 745 0.3 mg/kg

AMG 745 0.3 mg/kg IV QW

DRUG

AMG 745 1.0 mg/kg

AMG 745 1.0 mg/kg IV QW

DRUG

AMG 745 3.0 mg/kg

AMG 745 3.0 mg/kg IV QW

DRUG

Placebo

Placebo IV QW

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-05-31
Completion
2011-08-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00975104 on ClinicalTrials.gov